Express News | BoRui Medicine: Shareholder Advanced Manufacturing Fund plans to reduce holdings by no more than 3% of shares

Breakings18:35

BoRui Medicine (688166.SH): NDA for BGM0504 Injection for Weight Loss Indication Accepted

Bioray Pharma (688166.SH) announced that the new drug application (NDA) for the weight-loss indication of BGM0504 Injection, independently developed by its wholly owned subsidiary Bioray Pharmaceutical (Suzhou) Co., Ltd., has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

Zhitong FinanceJun 11 15:40

Spotlight: Capital Inflows and Technological Race Propel China's Brain-Computer Interface Industry to a New Tipping Point

① Specialized brain-computer interface (BCI) funds are being rapidly established across a spectrum of investors, from national-level entities and local state-owned capital to market-driven institutions; ② Although BCIs hold vast potential, the technology remains in an early stage, with many current products addressing only 'nice-to-have' rather than essential needs, and truly transformative medical applications are still some distance from large-scale commercialization; ③ Starting with vision-focused applications and ultimately progressing toward full sensory restoration is widely regarded as the most promising long-term trajectory for brain-computer interfaces.

cls.cnMay 24 21:46

BRIGHTGENE(688166):BGM0504 REPORTS EXCELLENT PHASE III DATA AS CLINICAL DEVELOPMENT OF INNOVATIVE METABOLIC PIPELINE CONTINUES

May 22 20:32

Kaiyuan Securities: The pharmaceutical industry is gradually transitioning from old to new growth drivers, with innovation leading to breakthroughs across multiple fronts.

Chemical pharmaceuticals and biologics: Differentiated pipelines continue to emerge, overseas expansion is accelerating, and collaboration models are becoming increasingly diverse, driving sustained growth in the innovative drug industry.

Zhitong FinanceMay 22 10:15

Oriental Securities: Twenty research studies from domestic companies have been selected for featured presentations at the ADA 2026 Annual Meeting, demonstrating the growing international competitiveness of China’s pipeline.

The bank believes that domestically developed pipelines are gradually demonstrating international competitiveness, particularly exhibiting significant advantages in cutting-edge areas such as small nucleic acid therapeutics, oral drugs, and ultra-long-acting formulations. In the future, they are expected to shift from rapid-follower strategies targeting crowded multinational corporation (MNC) segments toward innovation-led R&D focused on unmet clinical needs.

Zhitong FinanceMay 21 16:25